MaxCyte Announces Planned CFO Transition in 2026

Core Points - MaxCyte, Inc. announced that Chief Financial Officer Douglas Swirsky will transition from his role in the first half of 2026, with a structured search process initiated to find his successor [1][2] - Swirsky will remain in his position until a successor is appointed and will continue in an advisory role post-transition to support strategic initiatives [1][2] - The transition is not expected to impact the company's operations, financial reporting, or strategic priorities [2] Company Overview - MaxCyte is a leading cell-engineering company focused on advancing the discovery, development, and commercialization of next-generation cell therapies [3] - The company utilizes Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services to enable precise and scalable cell engineering [3] - With over 25 years of experience, MaxCyte aims to empower researchers globally to develop safe and effective treatments for human health [3]